| abstract |
585702 Disclosed herein are aqueous formulations comprising water and at least about 20 mg/mL of an antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, has a hydrodynamic diameter (Dh) which is at least about 50% less than the Dh of the antibody or had a hydrodynamic diameters of less than about 4 nm, or antigen-binding fragment thereof, in a buffered solution at the same concentration, and the antibody, or antigen-binding fragment thereof, has a molecular weight (Mw) greater than about 47 kDa. Specifically, wherein the antibody, or antigenbinding fragment thereof, is selected from the group consisting of adalimumab, alemtuzumab, CEA-Scan Arcitumomab (fab fragment), cetuximab, trastuzumab, imciromab pentetate, capromab pendetide, infliximab, abciximab, rituximab, basiliximab, palivizumab, nofetumomab, omalizumab, daclizumab, ibritumomab tiuxetan, muromonab-CD3, edrecolomab, gemtuzumab ozogamicin, golimumab, certolizumab pegol, eculizumab, ustekinumab, panitumumab, tositumomab and I131 tositumomab, and bevacizumab. |